This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Mark R. Mainous, MD; Patrick Tso, PhD; Rodney D. Berg, PhD; Edwin A. Deitch, MD

Arch Surg. 1991;126(1):33-37.

Abstract
• Bacteria have been documented to translocate from the gut to systemic organs, yet the exact route by which they translocate remains unclear. To determine the route of bacterial translocation, different dosages of zymosan were used to activate complement and cause systemic inflammation. At a zymosan dose of 0.1 mg/g, bacteria translocated only to the mesenteric lymph node complex, whereas at a dose of 0.5 mg/g the bacteria translocated systematically. In rats receiving 0.5-mg/g doses of zymosan, the bacteria appeared to reach systemic organs via the portal blood rather than via the mesenteric lymph, as bacteria were present in 87% of portal blood samples but only 25% of lymph samples. The number of bacteria exiting the portal vein was 11 500 times greater than the number exiting via the lymph. Thus, both the route and extent of bacterial translocation varies based on the magnitude of the inflammatory insult, with the portal blood being the major route of bacterial translocation to systemic organs.

(Arch Surg. 1991;126:33-37)

Author Affiliations
From the Departments of Surgery (Drs Mainous and Deitch), Physiology and Biophysics (Dr Tso), and Microbiology and Immunology (Dr Berg), Louisiana State University Medical Center, Shreveport, La.

Footnotes
Accepted for publication September 29, 1990.

Read before the Tenth Anniversary Meeting of the Surgical Infection Society, Cincinnati, Ohio, June 14, 1990.

Reprint requests to the Department of Surgery, LSUMC School of Medicine, 1501 Kings Highway, Shreveport, LA 71130-3932 (Dr Deitch).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Nitric Oxide Donor LA-419 [S-(6-Nitro-oxi-hexahydro-furo[3,2-b]furan-3-1-il)thioacetate] Prevents Intestinal Dysmotility, Bacterial Translocation, and Inflammation in a Rat Model of Enteritis
Porras et al.
J. Pharmacol. Exp. Ther. 2008;324:740-748.
ABSTRACT | FULL TEXT  

Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitronbenzene sulphonic acid
Llopis et al.
Gut 2005;54:955-959.
ABSTRACT | FULL TEXT  

Reducing Costs and Patient Morbidity in the Enterally Fed Intensive Care Unit Patient
Farber et al.
JPEN J Parenter Enteral Nutr 2005;29:S62-S69.
ABSTRACT | FULL TEXT  

The biological activity of a liposomal complete core lipopolysaccharide vaccine
Erridge et al.
Innate Immunity 2002;8:39-46.
ABSTRACT  

Increased Intestinal Permeability Is Associated with the Development of Multiple Organ Dysfunction Syndrome in Critically Ill ICU Patients
DOIG et al.
Am. J. Respir. Crit. Care Med. 1998;158:444-451.
ABSTRACT | FULL TEXT  

Elimination of Various Subpopulations of Macrophages and the Development of Multiple-Organ Dysfunction Syndrome in Mice
Nieuwenhuijzen et al.
Arch Surg 1997;132:533-539.
ABSTRACT